TAMIFLU®(oseltamivir phosphate)CAPSULESAND FOR ORAL SUSPENSION

First Page		Document Content
Organic chemistry Oseltamivir Guanidines Influenza treatment Zanamivir Viral neuraminidase Influenza vaccine Influenza Neuraminidase inhibitors Acetamides Chemistry		TAMIFLU®(oseltamivir phosphate)CAPSULESAND FOR ORAL SUSPENSION Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 1,07 MB Share Document on Facebook

	Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach DocID: 1vb6O - View Document
	FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A - Company Plans to Initiate Phase 2b Clinical Trial in Early 2018 Cambridge, MA – November 1, 2017 – Vi DocID: 1uP0v - View Document
	Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach DocID: 1uOXA - View Document
	XOFLUZATM (Baloxavir Marboxil) Tablets 10mg/20mg Approved for the Treatment of Influenza Types A and B in Japan Osaka, Japan, February 23, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, DocID: 1uL4E - View Document
	January 14, 2015 LACDPH Health Update: ACCESS TO ANTIVIRAL MEDICATION FOR TREATMENT OF INFLUENZA This message is intended for pharmacies and healthcare facilities as well as emergency medicine, internal medicine, urgent DocID: 1rZMZ - View Document